Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2017	Aug. 04, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2
Entity Registrant Name	ENZON PHARMACEUTICALS, INC.
Entity Central Index Key	0000727510
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ENZN
Entity Common Stock, Shares Outstanding		44,214,603

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash	$ 11,206	$ 7,639
Other receivable	3,500	0
Other current assets	127	270
Total current assets	14,833	7,909
Deferred tax assets, net	815	3,362
Total assets	15,648	11,271
Current liabilities:
Accounts payable	363	770
Accrued expenses and other current liabilities	124	170
Total current liabilities	487	940
Commitments and contingencies
Stockholders’ equity:
Preferred stock - $0.01 par value, authorized 3,000,000 shares; no shares issued and outstanding at June 30, 2017 and December 31, 2016	0	0
Common stock - $0.01 par value, authorized 170,000,000 shares; issued and outstanding 44,214,603 shares at June 30, 2017 and December 31, 2016	441	441
Additional paid-in capital	90,282	90,282
Accumulated deficit	(75,562)	(80,392)
Total stockholders’ equity	15,161	10,331
Total liabilities and stockholders’ equity	$ 15,648	$ 11,271

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	170,000,000	170,000,000
Common stock, shares issued	44,214,603	44,214,603
Common stock, shares outstanding	44,214,603	44,214,603

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenues:
Royalties	$ 6,775	$ 2,272	$ 8,215	$ 5,496
Miscellaneous income	0	0	0	42
Total revenues	6,775	2,272	8,215	5,538
Operating expenses:
General and administrative	337	436	686	1,157
Total operating expenses	337	436	686	1,157
Operating income and income before income tax expense	6,438	1,836	7,529	4,381
Income tax expense	2,253	801	2,699	1,829
Net income	$ 4,185	$ 1,035	$ 4,830	$ 2,552
Earnings per common share
Basic (in dollars per share)	$ 0.09	$ 0.02	$ 0.11	$ 0.06
Diluted (in dollars per share)	$ 0.09	$ 0.02	$ 0.11	$ 0.06
Weighted-average shares - basic	44,215	44,120	44,215	44,167
Weighted-average shares - diluted	44,215	44,120	44,215	44,167

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net income	$ 4,830	$ 2,552
Adjustments to reconcile net income to net cash provided by operating activities:
Deferred tax provision	2,547	1,829
Changes in operating assets and liabilities	(3,810)	(4,822)
Net cash provided by (used in) operating activities	3,567	(441)
Net increase (decrease) in cash	3,567	(441)
Cash at beginning of period	7,639	11,672
Cash at end of period	$ 11,206	$ 11,231

Description of Business

6 Months Ended

Jun. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Operations [Text Block]

(1) Description of Business

Enzon Pharmaceuticals, Inc. (together with its subsidiaries, “Enzon” or the “Company”) receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products, namely, PegIntron ®, Sylatron ®, Macugen ® and CIMZIA ®. The primary source of the Company’s royalty revenues in 2017 is the entrance into a Second Amendment (“Second Amendment”) to the Company’s Cross-License and Option Agreement (the “Agreement”) with Nektar Therapeutics, Inc. (“Nektar”), which generated non-recurring royalty revenues of $7 million in the six months ended June 30, 2017 (see below).

Previously, the primary source of the Company’s royalty revenues was sales of PegIntron, which is marketed by Merck & Co., Inc. (“Merck”). The Company currently has no clinical operations and limited corporate operations. The Company has no intention of resuming any clinical development activities or acquiring new sources of royalty revenues. Royalty revenues from sales of PegIntron accounted for approximately 5% and 72% of the Company’s total royalty revenues for the three months ended June 30, 2017 and 2016, respectively, and approximately 11% and 73% of the Company’s total royalty revenue in the six month periods ended June 30, 2017 and 2016, respectively, before adjustment for Merck’s recoupment of previously overpaid royalties. The effects of such recoupments were recorded as decreases of royalty revenues aggregating $564,000 for each of the three and six month periods ending June 30, 2017, as discussed in Note 11.

The Company was previously dedicated to the research and development of innovative therapeutics for patients with high unmet medical needs. Beginning in December 2012, the Company’s Board of Directors (the “Board”), with outside consultants, began a review of the possible sale or disposition of one or more corporate assets or a sale of the Company. At that time, the Company suspended substantially all clinical development activities with a goal of conserving capital and maximizing value returned to the Company’s stockholders. By April 2013, the review did not result in a definitive offer to acquire the Company or all or substantially all of the Company’s assets. At the same time, the Company announced that its Board intended to distribute excess cash, expected to arise from ongoing royalty revenues, in the form of periodic dividends to stockholders. On February 4, 2016, the Company’s Board adopted a Plan of Liquidation and Dissolution, the implementation of which has been postponed. (See Note 10.)

Under the Company’s existing agreements with certain third party licensees, the Company may be entitled to (i) potential future milestone payments contingent upon the achievement of certain milestones with respect to several other drug products in various stages of clinical and preclinical development and (ii) potential future royalty payments related to any future sales of these drug products. Due to the challenges associated with developing and obtaining approval for drug products, there is substantial uncertainty whether any of these milestones will be achieved. The Company also has no control over the time, resources and effort that these third party licensees may devote to their programs and limited access to information regarding or resulting from such programs. Accordingly, there can be no assurance that the Company will receive any of the milestone or royalty payments under these agreements.

As part of the Company’s sale of its former specialty pharmaceutical business that was completed in January 2010, the Company may be entitled to certain potential future milestone payments contingent upon the achievement of certain regulatory approval-related milestones with respect to Oncaspar from Shire plc (“Shire”), which assumed the milestone payment obligations when it acquired the Oncaspar product portfolio from Sigma-Tau Finanziaria S.p.A. in July 2015. Based on Shire’s May 2, 2017 investor presentation, the Company understands that Shire anticipates filing a Biologics License Application (“BLA”) for SC Oncaspar with the FDA in the third quarter of 2017. If FDA approval is obtained for SC Oncaspar, under its agreement, the Company would be entitled to a milestone payment of $7.0 million. There can be no assurance that Shire will file a BLA for SC Oncaspar with the FDA or that the FDA will approve the BLA, if filed. Accordingly, there can be no assurance that the Company will receive any of the milestone payments related to SC Oncaspar or any other such milestone payments resulting from its agreements with any of the Company’s other third party licensees. The Company will not recognize revenue until notification from Shire or any of the Company’s other third party licensees that the conditions necessitating payment of the milestone were satisfied and collection of the milestone payment is reasonably assured.

On June 26, 2017, the Company entered into the Second Amendment with Nektar, wherein Nektar agreed to buy-out all remaining payment obligations to the Company under the Agreement. In consideration for fully paid-up licenses under the Agreement and for the dismissal with prejudice of all claims and counterclaims asserted in the litigation with Nektar, Nektar agreed to pay the Company the sum of $7.0 million, which satisfies all future obligations of royalty payments pursuant to the Agreement, the first $3.5 million of which was paid within one business day of the effective date of the Second Amendment and the remaining $3.5 million of which will be paid within one business day of January 5, 2018. Accordingly, the Company recorded revenue of $7.0 million and an other receivable of $3.5 million in the second quarter of 2017. The Agreement also resulted in the dismissal with prejudice of all claims and counterclaims in the litigation with Nektar.

Basis of Presentation

6 Months Ended

Jun. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Accounting [Text Block]

(2) Basis of Presentation

Interim Financial Statements

The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with United States generally accepted accounting principles (U.S. GAAP) for interim financial information and Rule 10-01 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission. Accordingly, these financial statements do not include all of the information and footnotes required for complete annual financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include legal and contractual contingencies and income taxes. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.

Revenues

Royalties under the Company’s license agreements with third-parties and pursuant to the sale of its former specialty pharmaceutical business are recognized when reasonably determinable and earned through the sale of the product by the third-party and collection is reasonably assured. Notification from the third-party licensee of the royalties earned under the license agreement is the basis for royalty revenue recognition. This information generally is received from the licensees in the quarter subsequent to the period in which the sales occur.

New Accounting Pronouncements

6 Months Ended

Jun. 30, 2017

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Description of New Accounting Pronouncements Not yet Adopted [Text Block]

(3) New Accounting Pronouncements

In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-09 Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting. This update provides clarity, reduces the diversity in practice, and the cost and complexity when applying the guidance in Topic 718 to a change to the terms or conditions of a share-based payment award. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017, although early adoption is permitted. The Company does not believe that the updated standard will have a material effect on its financial statements.

Other recent ASU's issued by the FASB and guidance issued by the Securities and Exchange Commission did not, or are not believed by management to, have a material effect on the Company’s present or future consolidated financial statements.

Financial Instruments and Fair Value

6 Months Ended

Jun. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

(4) Financial Instruments and Fair Value

The carrying values of cash, other receivables, other current assets, accounts payable, accrued expenses and other current liabilities in the Company’s condensed consolidated balance sheets approximated their fair values at June 30, 2017 and December 31, 2016 due to their short-term nature.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Supplemental Cash Flow Information

6 Months Ended

Jun. 30, 2017

Supplemental Cash Flow Elements [Abstract]

Cash Flow, Supplemental Disclosures [Text Block]

(5) Supplemental Cash Flow Information

There were no income tax or interest payments made during the six months ended June 30, 2017.

There were estimated federal income tax payments of $135,000 and estimated New Jersey income tax payments of $1,000 made during the six months ended June 30, 2016. The $135,000 represented an over estimate of taxes due. In the second quarter of 2016, such amount was recorded as a receivable, included in other current assets, and subsequently collected.

Income Per Common Share

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

(6) Income Per Common Share

Basic earnings per common share is computed by dividing the income available to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Restricted stock units (nonvested shares) are not considered to be outstanding shares until the vesting criteria (service and/or performance) have been satisfied.

For purposes of calculating diluted earnings per common share, the denominator includes both the weighted-average number of shares of common stock outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and nonvested shares using the treasury stock method and shares issuable under the employee stock purchase plan (ESPP). There were no common stock equivalents during any of the periods presented. Income per common share information is as follows (in thousands, except per share amounts):

	Three months ended June 30,				Six months ended June 30,
	2017		2016		2017		2016
Income Per Common Share – Basic and Diluted:
Net income	$	4,185	$	1,035	$	4,830	$	2,552

Weighted-average common shares outstanding		44,215		44,120		44,215		44,167

Basic and diluted income per share	$	0.09	$	0.02	$	0.11	$	0.06

As of June 30, 2017 and 2016, options for 41,787 and 218,719 shares, respectively, were outstanding that have been excluded from the calculation of diluted weighted average shares outstanding, as they would be anti-dilutive since the respective options’ strike price was greater than the current market price of the shares.

Stock-Based Compensation

6 Months Ended

Jun. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

(7) Stock-Based Compensation

Stock Options and Restricted Stock Units (RSUs or Nonvested Shares)

During the six months ended June 30, 2017, no options were granted and the Company incurred no stock-based compensation expense. No RSUs were outstanding as of June 30, 2017.

During the six months ended June 30, 2016, the Company incurred no stock-based compensation expense. Shares were withheld to pay approximately $6,000 of taxes on behalf of employees because restricted stock units (RSUs) vested during the period, which had no effect on additional paid-in capital.

Activity related to stock options and nonvested shares during the six months ended June 30, 2017 and related balances outstanding as of that date are reflected below (in thousands):

	Stock
	Options
Outstanding at January 1, 2017		219
Granted		-
Exercised and vested		-
Expired and forfeited		177
Outstanding at June 30, 2017		42

Options vested and expected to vest at June 30, 2017		42

Options exercisable at June 30, 2017		42

Income Taxes

6 Months Ended

Jun. 30, 2017

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

(8) Income Taxes

The Company incurred tax expense of approximately $2.7 million for the first half of 2017 of which approximately $2.3 million was incurred during the second quarter of 2017. The effective tax rate for the three-month period ended June 30, 2017 was 35% compared to 41.7% for the corresponding period in the prior year. The reduction in the rate is attributable to changes in projected income for the year. In addition, the Company recorded tax expense of $1.4 million as a discrete item for the three-month period ended June 30, 2017 for the tax effect of projected income reduction in future years. The Company expects to continue to utilize the deferred tax asset through the remainder of 2017, resulting in an expected effective tax rate of approximately 30% for the year.

After reducing its deferred tax assets by approximately $2.5 million during six months ended June 30, 2017, the Company continues to provide a valuation allowance against all of its deferred tax assets except for NOLs expected to be utilized in the 2018 and 2019 tax years as the Company believes it is more likely than not that these remaining deferred tax assets will not be realized. Management of the Company will continue to assess the need for this valuation allowance and will make adjustments to it when appropriate.

During the six months ended June 30, 2016, the Company recorded approximately $1.8 million of income tax expense for U.S. federal and New Jersey state income tax, substantially all of which related to a reduction of the Company’s net deferred tax assets. Of this amount, approximately, $801,000, was recorded in the second quarter of 2016.

Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions. Interest and penalties, if any, related to unrecognized tax benefits, would be recognized as income tax expense.

Commitments and Contingent Liabilities

6 Months Ended

Jun. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

(9) Commitments and Contingent Liabilities

Commencing on March 1, 2016, the Company changed the location of its principal executive offices to 20 Commerce Drive, Suite 135, Cranford, New Jersey, 07016. The Company entered into an office service agreement with Regus Management Group, LLC (“Regus”) for use of office space at this location effective March 1, 2016. Under the agreement, in exchange for the Company’s right to use the office space at this location, the Company was required to pay Regus an initial service retainer of $2,418 and thereafter pay Regus a monthly fee of $1,209 until February 28, 2017. This agreement was renewed for another year, until February 28, 2018, for a monthly fee of $1,229.

The Company has been involved in various claims and legal actions arising in the ordinary course of business. In the opinion of management, the ultimate disposition of these matters will not have a material effect on the Company’s consolidated financial position, results of operations, or liquidity.

Plan of Liquidation and Dissolution

6 Months Ended

Jun. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Liquidation Basis of Accounting [Text Block]

(10) Plan of Liquidation and Dissolution

On February 4, 2016, the Company’s Board adopted a Plan of Liquidation and Dissolution (the “Plan of Liquidation and Dissolution”), pursuant to which the Company would, subject to obtaining requisite stockholder approval, be liquidated and dissolved in accordance with Sections 280 and 281 (a) of the General Corporation Law of the State of Delaware. In approving the Plan of Liquidation and Dissolution, the Company’s Board had considered, among other factors, the ability of the Company to obtain no-action relief from the SEC to suspend certain of the Company’s reporting obligations under the Securities Exchange Act of 1934, as amended, and the anticipated cost savings if such relief is granted by the SEC. Upon further review, the Company concluded that the SEC was unlikely to grant such relief to the Company in 2016. Accordingly, after further consideration, the Company’s Board determined that it would be fair, advisable and in the best interests of the Company and its stockholders to postpone seeking stockholder approval of the Plan of Liquidation and Dissolution until a later time to be determined by the Company’s Board.

If dissolution and liquidation of the Company pursuant to the Plan of Liquidation and Dissolution are approved by the Company’s stockholders and implemented by management, it is expected that the Company’s corporate existence will continue for the purpose of winding up its business and affairs through the year 2021, consistent with the expiration of the Company’s existing license arrangements that generate its royalty revenues. The Company’s future royalty revenues are forecasted to aggregate approximately $13 million from the beginning of 2017 through the end of 2021. This forecast is based upon a variety of estimates and numerous assumptions made by the Company’s management with respect to, among other matters, forecasted sales of the drug products for which the Company has the right to receive royalties and other matters, many of which are difficult to predict, are subject to significant uncertainties, and are beyond the Company’s control. As a result, there can be no assurance that the estimates and assumptions upon which this forecast is based will prove accurate, that the projected results will be realized or that actual results will not be substantially higher or lower than forecasted.

Royalty Revenues and Accounts Payable

6 Months Ended

Jun. 30, 2017

Royalty Revenues and Accounts Payable [Abstract]

Royalty Revenues and Accounts Payable [Text Block]

(11) Royalty Revenues and Accounts Payable

In March 2017, Merck notified the Company that, during the second and third quarters of 2016, it had made an overpayment to Enzon of approximately $770,000 in royalties (net of a 25% royalty interest that the Company had previously sold). This was due to a previous misunderstanding regarding the date on which the Company’s right to receive royalties from U. S. sales of PegIntron expired, which Merck then advised had occurred in February 2016. Merck notified the Company that it intended to recover such overpayment from the Company by reducing future royalties to which the Company would otherwise be entitled from Merck until the full amount of the overpayment had been recouped. Accordingly, in the December 31, 2016 financial statements, the Company reduced its previously recorded revenues by the net $770,000 overpayment and recorded a corresponding liability to Merck in accounts payable.

During the three-month period ending March 31, 2017, Merck reported net royalties earned by the Company aggregated approximately $636,000 and withheld that amount as a partial recoupment of its overpayment. That left a balance due to Merck of approximately $134,000 at March 31, 2017.

During the second quarter of 2017, Merck reported net royalties earned by the Company of approximately $335,000. From this amount, Merck would have withheld approximately $134,000, as the balance of the recoupment of the previously reported overpayment. This would have left approximately $201,000 as due to the Company.

However, in the second quarter of 2017, Merck notified the Company that they discovered additional overpayments to the Company resulting from the inaccuracy as to the date on which the Company’s right to receive royalties from various countries’ sales of PegIntron expired. Such net overpayment to Enzon aggregated approximately $563,000 in royalties during 2015 and 2016. Merck notified the Company that it intended to recover such overpayment from the Company by reducing future royalties to which the Company would otherwise be entitled from Merck until the full amount of the overpayment had been recouped. Accordingly, in the June 30, 2017 financial statements, the Company reduced its previously recorded revenues by the net $563,000 overpayment. Merck withheld the $201,000 of the royalties otherwise due for the second quarter of 2017 as a partial recoupment. As a result, the Company recorded the $363,000 remaining to be recouped by Merck as a liability to Merck in accounts payable at June 30, 2017.

Basis of Presentation (Policies)

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Interim Financial Statements [Policy Text Block]

Interim Financial Statements

Consolidation, Policy [Policy Text Block]

Principles of Consolidation

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

Revenue Recognition, Policy [Policy Text Block]

Revenues

Income Per Common Share (Tables)

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

Income per common share information is as follows (in thousands, except per share amounts):

	Three months ended June 30,				Six months ended June 30,
	2017		2016		2017		2016
Income Per Common Share – Basic and Diluted:
Net income	$	4,185	$	1,035	$	4,830	$	2,552

Weighted-average common shares outstanding		44,215		44,120		44,215		44,167

Basic and diluted income per share	$	0.09	$	0.02	$	0.11	$	0.06

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Share-based Compensation, Activity [Table Text Block]

Activity related to stock options and nonvested shares during the six months ended June 30, 2017 and related balances outstanding as of that date are reflected below (in thousands):

	Stock
	Options
Outstanding at January 1, 2017		219
Granted		-
Exercised and vested		-
Expired and forfeited		177
Outstanding at June 30, 2017		42

Options vested and expected to vest at June 30, 2017		42

Options exercisable at June 30, 2017		42

Description of Business (Details Textual) - USD ($)	1 Months Ended	3 Months Ended			6 Months Ended
Description of Business (Details Textual) - USD ($)	Mar. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Description of Business [Line Items]
Royalty Revenues From Sales Percentage		5.00%		72.00%	11.00%	73.00%
Royalty Revenue, Total		$ 6,775,000		$ 2,272,000	$ 8,215,000	$ 5,496,000
Other Receivables, Net, Current		3,500,000			3,500,000		$ 0
Payment Of Milestone Payments					7,000,000
Merck Co Inc [Member]
Description of Business [Line Items]
Decreases Of Royalty Revenues		564,000			564,000
Proceeds from Royalties Received	$ 770,000		$ 636,000		335,000
Nektar Therapeutics, Inc [Member]
Description of Business [Line Items]
Royalty Revenue, Total					7,000,000
Proceeds from Royalties Received					3,500,000
Other Receivables, Net, Current		$ 3,500,000			$ 3,500,000

Supplemental Cash Flow Information (Details Textual)	6 Months Ended
Supplemental Cash Flow Information (Details Textual)	Jun. 30, 2017 USD ($)
Dividends Payable [Line Items]
Income Taxes Paid	$ 135,000
Interest Paid, Net	0
New Jersey Division of Taxation [Member]
Dividends Payable [Line Items]
Income Taxes Paid	$ 1,000

Income Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Per Common Share - Basic and Diluted:
Net income	$ 4,185	$ 1,035	$ 4,830	$ 2,552
Weighted-average common shares outstanding	44,215	44,120	44,215	44,167
Basic and diluted income per share	$ 0.09	$ 0.02	$ 0.11	$ 0.06

Income Per Common Share (Details Textual) - shares	6 Months Ended
Income Per Common Share (Details Textual) - shares	Jun. 30, 2017	Jun. 30, 2016
Employee Stock Option [Member]
Earnings Per Common Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	41,787	218,719

Stock-Based Compensation (Details) shares in Thousands	6 Months Ended
Stock-Based Compensation (Details) shares in Thousands	Jun. 30, 2017 shares
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Options, Outstanding at January 1, 2017, Stock Options	219
Granted, Stock Options	0
Exercised and vested, Stock Options	0
Expired and forfeited, Stock Options	177
Options, Outstanding at June 30, 2017, Stock Options	42
Options vested and expected to vest at June 30, 2017, Stock Options	42
Options exercisable at June 30, 2017, Stock Options	42

Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended			12 Months Ended
Income Taxes (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2017	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Income Taxes [Line Items]
Deferred Tax Assets, Net, Current	$ 2,500			$ 2,500
Income Tax Expense (Benefit)	2,253	$ 801		$ 2,699	$ 1,829
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount	$ 1,400
Effective Income Tax Rate Reconciliation, Percent	35.00%					41.70%
Scenario, Forecast [Member]
Income Taxes [Line Items]
Effective Income Tax Rate Reconciliation, Percent			30.00%

Commitments and Contingent Liabilities (Details Textual) - Regus Management Group, LLC [Member] - USD ($)		6 Months Ended
	Mar. 01, 2017	Jun. 30, 2017	Mar. 01, 2016
Loss Contingencies [Line Items]
Security Deposit			$ 2,418
Operating Leases, Rent Expense	$ 1,209	$ 1,229

Plan of Liquidation and Dissolution (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		60 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2021
Royalty Revenue, Total	$ 6,775	$ 2,272	$ 8,215	$ 5,496
Scenario, Forecast [Member]
Royalty Revenue, Total					$ 13,000

Royalty Revenues and Accounts Payable (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Mar. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2017	Dec. 31, 2016
Accounts Payable, Current		$ 363,000		$ 363,000	$ 770,000
Merck Co Inc [Member]
Royalty Payments Withheld				134,000
Proceeds from Royalties Received	$ 770,000		$ 636,000	335,000
Accrued Royalties		201,000	$ 134,000	201,000	$ 770,000
Decreases Of Royalty Revenues		$ 564,000		$ 564,000
Percentage of Equity Interest Sold			25.00%

Stock-Based Compensation (Details Textual)	6 Months Ended
Stock-Based Compensation (Details Textual)	Jun. 30, 2017 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Employee Service Share Based Compensation Tax Payments	$ 6,000